• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对肿瘤网络中曲妥珠单抗辅助治疗的检测和应用的回顾——我们治疗的患者合适吗？

Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?

机构信息

Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK.

出版信息

Clin Oncol (R Coll Radiol). 2010 May;22(4):289-93. doi: 10.1016/j.clon.2010.02.011. Epub 2010 Mar 26.

DOI:10.1016/j.clon.2010.02.011
PMID:20347281
Abstract

This review of practice assessed all early breast cancer patients diagnosed over 12 months to determine the frequency of human epidermal growth factor receptor 2 (HER2) positivity and trastuzumab use. The frequency of HER2 positivity in routine practice (185/1319; 14%) was less than expected. A significant proportion of patients (56/185; 30%) did not receive trastuzumab, largely due to concerns about chemotherapy tolerability.

摘要

本实践回顾评估了所有在 12 个月内确诊的早期乳腺癌患者，以确定人类表皮生长因子受体 2（HER2）阳性和曲妥珠单抗使用的频率。常规实践中 HER2 阳性的频率（185/1319；14%）低于预期。相当一部分患者（56/185；30%）未接受曲妥珠单抗治疗，主要是由于担心化疗耐受性。

相似文献

1
Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?对肿瘤网络中曲妥珠单抗辅助治疗的检测和应用的回顾——我们治疗的患者合适吗？
Clin Oncol (R Coll Radiol). 2010 May;22(4):289-93. doi: 10.1016/j.clon.2010.02.011. Epub 2010 Mar 26.
2
HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment.在管理式医疗环境中对乳腺癌进行HER2检测及后续曲妥珠单抗治疗。
Oncologist. 2009 Aug;14(8):760-8. doi: 10.1634/theoncologist.2008-0288. Epub 2009 Aug 14.
3
Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.在荷兰，曲妥珠单抗联合辅助化疗治疗非转移性乳腺癌的实施情况。
Breast Cancer Res Treat. 2011 Aug;129(1):229-33. doi: 10.1007/s10549-011-1451-0. Epub 2011 Mar 24.
4
Controversies in the use of adjuvant trastuzumab (Herceptin).辅助性曲妥珠单抗（赫赛汀）使用中的争议。
J Br Menopause Soc. 2006 Dec;12(4):172-4. doi: 10.1258/136218006779160517.
5
Trastuzumab administration associated with change in HER2 status.曲妥珠单抗给药与HER2状态改变相关。
Clin Breast Cancer. 2008 Aug;8(4):366-9. doi: 10.3816/CBC.2008.n.044.
6
HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales.
Clin Oncol (R Coll Radiol). 2010 Dec;22(10):894. doi: 10.1016/j.clon.2010.07.003. Epub 2010 Aug 13.
7
Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.早期HER2阳性乳腺癌初次治疗后使用曲妥珠单抗可降低复发率。
Cancer Treat Rev. 2006 Apr;32(2):144-8. doi: 10.1016/j.ctrv.2006.01.005. Epub 2006 Mar 6.
8
Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.优化人表皮生长因子受体2阳性乳腺癌的治疗：T代表曲妥珠单抗、肿瘤大小和治疗策略。
J Clin Oncol. 2009 Dec 1;27(34):5671-3. doi: 10.1200/JCO.2009.24.2222. Epub 2009 Nov 2.
9
Trastuzumab in breast cancer.曲妥珠单抗在乳腺癌中的应用
N Engl J Med. 2006 Feb 9;354(6):640-4; author reply 640-4.
10
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.血清HER2/neu在接受曲妥珠单抗治疗的转移性乳腺癌患者无进展生存期监测及预测中的临床应用
Breast Cancer Res. 2005;7(4):R436-43. doi: 10.1186/bcr1020. Epub 2005 Apr 8.

引用本文的文献

1
The use of trastuzumab affected by health insurance policy in Jiangsu Province of China.中国江苏省医疗保险政策对曲妥珠单抗使用的影响。
Transl Cancer Res. 2021 Jan;10(1):509-519. doi: 10.21037/tcr-20-3329.
2
Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort Study.术前全身治疗的乳腺癌患者中CPS + EG、Neo-Bioscore和改良Neo-Bioscore的评估：一项多中心队列研究
Front Oncol. 2021 Mar 16;11:606477. doi: 10.3389/fonc.2021.606477. eCollection 2021.
3
Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
人表皮生长因子受体2阳性乳腺癌治疗的演变格局与生物类似药的未来。
Breast. 2017 Apr;32:199-216. doi: 10.1016/j.breast.2017.01.010. Epub 2017 Feb 23.
4
Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer.局部HER2阳性乳腺癌女性辅助曲妥珠单抗的未启动和早期停用
Breast Cancer. 2014 Nov;21(6):780-5. doi: 10.1007/s12282-014-0543-1. Epub 2014 Jun 6.
5
Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?探讨在英国大型癌症网络中辅助曲妥珠单抗在 HER2 阳性乳腺癌患者中的使用和影响。国际临床试验的结果是否对威尔士东南部的患者有类似的益处？
Br J Cancer. 2012 Jan 3;106(1):32-8. doi: 10.1038/bjc.2011.506. Epub 2011 Nov 22.
6
Genomic testing and therapies for breast cancer in clinical practice.临床实践中的乳腺癌基因组检测和治疗。
J Oncol Pract. 2011 May;7(3 Suppl):e1s-7s. doi: 10.1200/JOP.2011.000299.
7
A pharmacogenomic method for individualized prediction of drug sensitivity.一种用于个体化预测药物敏感性的药物基因组学方法。
Mol Syst Biol. 2011 Jul 19;7:513. doi: 10.1038/msb.2011.47.
8
HER2 evaluation and its impact on breast cancer treatment decisions.人表皮生长因子受体2（HER2）评估及其对乳腺癌治疗决策的影响。
Public Health Genomics. 2012;15(1):1-10. doi: 10.1159/000325746. Epub 2011 May 3.